PYPDHealthcare · BiotechnologyThe 4 Wall Street analysts covering PolyPid Ltd. hold a median 12-month price target of $13 — +155.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 8 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores PolyPid Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (97): The share price has been relatively steady.
Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PYPD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +155.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $13 |
| 11 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | $13 |
| 13 Nov 2025 | Roth Capital | Maintains | Buy | — |
| 14 Aug 2025 | Craig-Hallum | Maintains | Buy | — |
| 13 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 June 2025 | Roth Capital | Maintains | Buy | — |
| 17 June 2025 | JMP Securities | Maintains | Market Outperform | — |
| 9 June 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 June 2025 | Roth Capital | Initiates | Buy | — |
| 2 June 2025 | HC Wainwright & Co. | Assumes | Buy | $11 |
| 14 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Dec 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Nov 2024 | Craig-Hallum | Initiates | Buy | — |
| 2 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PYPD appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, PolyPid Ltd. returned +42.9% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 5% of US stocks
Cheaper than 76% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 6% of US stocks
Higher than 5% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
PolyPid Ltd. has a market value of $104.2M and an enterprise value of $99.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$31.5M.
Diluted earnings per share, trailing twelve months: $−1.48.
Trailing P/E: −2.4×; forward P/E: −4.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
PolyPid Ltd. employs 69 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own PolyPid Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
PolyPid's CEO stated the company is approaching a November 28 PDUFA date for D-PLEX100, its lead candidate for preventing surgical site infections in colorectal surgery patients, during the Lytham Partners Fall 2026 Investor Conference.
Why it matters — The upcoming FDA decision date for D-PLEX100 represents a key regulatory milestone for PolyPid's lead product candidate.
PolyPid announced that the European Medicines Agency has validated its Marketing Authorization Application for D-PLEX₁₀₀, which was submitted last month. This marks progress in the regulatory review process for the company's product in Europe.
Why it matters — EMA validation of the D-PLEX₁₀₀ application is a meaningful regulatory milestone that advances the product toward a potential European market decision.
PolyPid and ADVANZ PHARMA have mutually agreed to terminate their 2022 exclusive License, Distribution and Supply Agreement for D-PLEX₁₀₀ in Europe, returning European commercialization rights to PolyPid. The company said this expands its global commercialization opportunities.
Why it matters — PYPD watchers would care because recovering European commercialization rights changes how PolyPid can control and pursue marketing of D-PLEX₁₀₀ in that region, though the strategic impact will depend on how the company next utilizes those rights.
PolyPid Ltd. announced that its senior management will participate in several upcoming fall investor conferences. The company is an innovative biopharmaceutical firm focused on improving patient outcomes through enhanced treatment effectiveness.
Why it matters — The announcement signals increased investor visibility and potential engagement opportunities for PolyPid watchers ahead of the fall conference season.
Seeking Alpha published the Q2 2026 earnings call transcript for PolyPid Ltd. (PYPD). The item provides the transcript of the company's second-quarter 2026 earnings call.
Why it matters — PYPD watchers can review the earnings call transcript for management's discussion of the company's Q2 2026 performance and outlook.
The 4 Wall Street analysts covering PolyPid Ltd. have a median 12-month price target of $13, with estimates ranging from $8 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering PolyPid Ltd., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PolyPid Ltd. 56 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, PolyPid Ltd. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +155.1% from the last close, and Ticker Nerd's factor model ranks PolyPid Ltd. 56 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering PolyPid Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PYPD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $14 over the next 12 months.
PolyPid Ltd. returned +42.9% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
PolyPid Ltd. is a biopharmaceutical company focused on developing long-acting, locally administered therapeutics designed to deliver treatment precisely at the site of care.
The most recent item we track (MarketBeat, 4 Oct 2026): "PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data". PolyPid's CEO stated the company is approaching a November 28 PDUFA date for D-PLEX100, its lead candidate for preventing surgical site infections in colorectal surgery patients, during the Lytham Partners Fall 2026 Investor Conference.
PolyPid Ltd. is a biopharmaceutical company focused on developing long-acting, locally administered therapeutics designed to deliver treatment precisely at the site of care. Its core platform, PLEX, is used to create controlled-release drug formulations that aim to improve therapeutic performance and address unmet medical needs across surgical care and other specialty areas. The company’s lead product candidate, D-PLEX100, is being developed for the prevention of surgical site infections, while its pipeline also includes oncology-focused programs such as OncoPLEX. PolyPid Ltd. works across clinical development, formulation design, and drug delivery technology, positioning itself in the broader market for targeted medicines and advanced pharmaceutical delivery systems. The company is headquartered in Petach Tikva, Israel.
CEO Ms. Dikla Czaczkes Akselbrad · 69 employees · Israel · https://www.polypid.com
